Enanta Pharmaceuticals Advances Zelicapavir into Registrational Phase 2b/3 for RSV in Adults and Phase 2b in Pediatrics

summarizeSummary

Enanta Pharmaceuticals is advancing its RSV drug, zelicapavir, into late-stage clinical trials for both adults and children after a successful FDA meeting, targeting a multi-billion dollar market.

check_boxKey Events

• Zelicapavir Enters Registrational Phase 2b/3 for RSV in Adults

  The company will initiate a registrational Phase 2b/3 clinical trial for zelicapavir in high-risk adults with RSV in Q4 2026, with topline Phase 2b data expected in 2027. This follows a successful End-of-Phase 2 meeting with the FDA.

• Phase 2b Trial Initiated for Pediatric RSV Patients

  A Phase 2b clinical trial for zelicapavir in pediatric patients with RSV is planned to start in Q3 2026, with topline data also expected in 2027.

• Significant Market Opportunity

  Management estimates the global market opportunity for an oral RSV antiviral in children and high-risk adults to be over $2 billion, with a potential total addressable population of over 3 million patients in the U.S. alone.

• Clear Regulatory Pathway

  The successful End-of-Phase 2 meeting with the FDA provides a clear and efficient pathway for advancing zelicapavir into a registrational program.

auto_awesomeAnalysis

Enanta Pharmaceuticals announced a significant advancement in its zelicapavir program for Respiratory Syncytial Virus (RSV), moving into registrational Phase 2b/3 trials for high-risk adults and Phase 2b trials for pediatric patients. This follows a successful End-of-Phase 2 meeting with the FDA, establishing a clear and efficient pathway for development. Zelicapavir targets a multi-billion dollar market with no currently approved treatments, representing a major de-risking event and potential value driver for the company.